MK-8527在未治疗HIV-1成人中的抗病毒活性、药代动力学与安全性:两项开放标签1期研究
两项1期单次给药研究评估了新型口服核苷类逆转录酶易位抑制剂MK-8527在未接受过抗逆转录病毒治疗的HIV-1成人中的抗病毒活性、药代动力学与安全性。37名参与者单次口服0.25至10 mg MK-8527后,0.5至10 mg剂量组第7天HIV RNA平均下降≥1.0 log10 copies/mL,抑菌商数在≥0.5 mg时超过3,所有剂量耐受良好。
要点
- 单次口服MK-8527 0.5 mg即可使HIV RNA第7天下降≥1.0 log10 copies/mL。
- ≥0.5 mg剂量下抑菌商数(C168/IC50)超过3。
- 各剂量水平耐受良好,不良事件多为轻中度且与研究治疗无关。
核心结论
- 在未接受过抗逆转录病毒治疗的HIV-1成人中,单次口服MK-8527低至0.5 mg即可在第7天使HIV RNA下降≥1.0 log10 copies/mL。
研究设计与样本
- 两项1期开放标签单次给药单药治疗研究,共37名未接受过抗逆转录病毒治疗的HIV-1成人完成。
- 参与者接受MK-8527单次口服剂量0.25、0.5、1、3或10 mg。
主要发现
- 单次给药0.5至10 mg后,第7天HIV RNA平均下降≥1.0 log10 copies/mL。
- 单次给药≥0.5 mg时,抑菌商数(168小时MK-8527-TP浓度C168与IC50平均细胞内浓度之比)超过3。
- 所有剂量水平耐受良好,研究者判定不良事件与研究治疗无关且数量有限、多为轻中度。
临床怎么用
- 提示MK-8527作为HIV预防候选药物具有进一步临床开发潜力。
局限性
- 两项均为1期开放标签单次给药研究,样本量有限(共37人),仅评估短期安全性与药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MK-8527 is a novel oral nucleoside reverse transcriptase translocation inhibitor under clinical development as HIV-1 (HIV) prevention. Two Phase 1 single-dose monotherapy studies were conducted to evaluate antiretroviral activity, pharmacokinetics (PK), and safety of MK-8527 in adults with HIV who had not previously taken antiretroviral agents. METHODS: In 2 Phase 1 studies, participants received a single oral dose of MK-8527 (0.25, 0.5, 1, 3, or 10 mg). Reduction in viral load (measured as log10 plasma HIV RNA copies/mL at 7 days post-dose), PK of plasma MK-8527 through 7 days, intracellular MK-8527-triphosphate (TP, the active form of MK-8527) through 28 days, exposure-response relationship, and safety through 28 days were assessed. Adverse events were descriptively summarized. RESULTS: In total, 37 participants completed the studies. After single doses of MK-8527 0.5 to 10 mg, the mean decrease in HIV RNA at 7 days-post dose was ≥1.0 log10 copies/mL. The inhibitory quotient (defined as the ratio of MK-8527-TP concentration at 168 hours post-dose [C168] to the mean intracellular concentration of MK-8527-TP at the half-maximal inhibitory concentration [IC50]) exceeded 3 at single doses of ≥0.5 mg. MK-8527 at all dose levels was well tolerated, with a limited number of mild or moderate adverse events that were determined by investigators to be unrelated to the study treatment. CONCLUSIONS: In adults with HIV who had not previously taken antiretroviral agents, single doses of MK-8527 as low as 0.5 mg achieved ≥1.0 log10 decreases in HIV RNA at 7 days post-dose administration. CLINICAL TRIALS REGISTRATION: www.clinicaltrials.gov NCT03615183, NCT05494736.
引用
- Carstens RP, Kapoor Y, Vargo RC, et al. Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. Clin Infect Dis. 2026. PMID: 41830320. doi:10.1093/cid/ciag135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。